Investing.com - Le cours de l’action GSK Plc (NYSE: GSK) a chuté de 5% après qu’un comité consultatif de la Food and Drug ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

L’indice phare FTSE 100 a augmenté de 0,2% et la livre sterling a gagné 0,2% face au dollar pour dépasser 1,34. L’indice DAX ...

Relief over a US-EU trade deal today benefited the FTSE 100 index in a session when leading European benchmarks rose by as ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...

GSK is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.52; value investors should ...

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also ...